{"canonical":"https://abierto.us/vendors/4j-therapeutics-inc-szcgv7lqjkr4","key":"SZCGV7LQJKR4","name":"4J THERAPEUTICS INC","uei":"SZCGV7LQJKR4","city":"PALO ALTO","state":"CA","awards":1,"obligated":"52484360.00","notices_won":8,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541714","cage":"9DFF0","parent_name":"4J THERAPEUTICS INC","also_known_as":[],"country":"USA","actions":5,"first_action":"2024-09-18","last_action":"2026-08-21","breakdowns":{"naics":[{"key":"541714","name":null,"awards":1,"obligated":"52484360.00"}],"places":[{"key":"CA","name":null,"awards":1,"obligated":"52484360.00"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":1,"obligated":"52484360.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"52484360.00"}],"competition":[{"key":"FULL AND OPEN COMPETITION","name":null,"awards":1,"obligated":"52484360.00"}],"product_service_codes":[{"key":"AN13","name":null,"awards":1,"obligated":"52484360.00"}]},"awards_list":[{"award_key":"CONT_AWD_75A50124C00052_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50124C00052_7505_-NONE-_-NONE-/","piid":"75A50124C00052","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"SZCGV7LQJKR4","recipient_name":"4J THERAPEUTICS INC","recipient_uei":"SZCGV7LQJKR4","recipient_cage":"9DFF0","recipient_city":"PALO ALTO","recipient_state":"CA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-09-18","last_action_date":"2026-08-21","actions":5,"obligated":"52484360.00","current_total_value":"52484360.00","potential_total_value":"351633257.00","naics":"541714","psc":"AN13","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND","method":null,"confidence":null,"evidence":null,"opportunity_key":"BAA23100SOL00004","opportunity_title":"Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)"}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}